Abstract
The integrin family of cell surface receptors were principally thought to be involved in cell adhesion. Intense study has shown that these glycoproteins also regulate a diverse range of physiological processes. Inappropriate activation of integrins has been implicated in many pathological processes. Recent studies have shown that these molecules play a key role in the early stages of liver metastasis in colorectal cancer. In vivo experiments have demonstrated that integrins are involved in tumour cell targeting, arrest, adhesion and migration within the hepatic microcirculation. Indeed functional blocking of specific integrins has been shown to significantly impair these early stages of metastasis development. This review examines the current knowledge of integrin participation in this area and highlights the future therapeutic implications. Future targeted therapy against specific integrins would allow not only functional blocking but would provide the potential to deliver specific anti-cancer therapy.
Keywords: Colorectal cancer, liver metastasis, integrin, treatment
Current Pharmaceutical Design
Title: Integrins: A Method of Early Intervention in the Treatment of Colorectal Liver Metastases
Volume: 14 Issue: 3
Author(s): Alexander M. Seifalian, John H. Robertson, Arthur M. Iga, Kevin M. Sales and Marc C. Winslet
Affiliation:
Keywords: Colorectal cancer, liver metastasis, integrin, treatment
Abstract: The integrin family of cell surface receptors were principally thought to be involved in cell adhesion. Intense study has shown that these glycoproteins also regulate a diverse range of physiological processes. Inappropriate activation of integrins has been implicated in many pathological processes. Recent studies have shown that these molecules play a key role in the early stages of liver metastasis in colorectal cancer. In vivo experiments have demonstrated that integrins are involved in tumour cell targeting, arrest, adhesion and migration within the hepatic microcirculation. Indeed functional blocking of specific integrins has been shown to significantly impair these early stages of metastasis development. This review examines the current knowledge of integrin participation in this area and highlights the future therapeutic implications. Future targeted therapy against specific integrins would allow not only functional blocking but would provide the potential to deliver specific anti-cancer therapy.
Export Options
About this article
Cite this article as:
Seifalian M. Alexander, Robertson H. John, Iga M. Arthur, Sales M. Kevin and Winslet C. Marc, Integrins: A Method of Early Intervention in the Treatment of Colorectal Liver Metastases, Current Pharmaceutical Design 2008; 14 (3) . https://dx.doi.org/10.2174/138161208783413284
DOI https://dx.doi.org/10.2174/138161208783413284 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Proteases as Anti-Cancer Targets - Molecular and Biological Basis for Development of Inhibitor-Like Drugs Against Cancer
Anti-Cancer Agents in Medicinal Chemistry Modulators of the microRNA Biogenesis Pathway via Arrayed Lentiviral Enabled RNAi Screening for Drug and Biomarker Discovery
Combinatorial Chemistry & High Throughput Screening Anticancer Agents: VTA or VDA
Current Bioactive Compounds Synthesis and Cytotoxic Evaluation of Quinazolin-4(3H)-one Derivatives Bearing Thiocarbamate, Thiourea or N-Methyldithiocarbamate Side Chains
Medicinal Chemistry In Vivo Bio-imaging Using Chlorotoxin-based Conjugates
Current Pharmaceutical Design Radiolabeled Small Molecule Inhibitors of VEGFR - Recent Advances
Current Pharmaceutical Design Radiopharmaceutical Applications of Organometallic Technetium and Rhenium Complexes
Current Inorganic Chemistry (Discontinued) Vitamin D and Cancer Mortality: Systematic Review of Prospective Epidemiological Studies
Anti-Cancer Agents in Medicinal Chemistry State of the Art on Carbonic Anhydrase Modulators for Biomedical Purposes
Current Medicinal Chemistry Targeting c-MET/HGF Signaling Pathway in Upper Gastrointestinal Cancers: Rationale and Progress
Current Drug Targets The Potential Targets and Mechanisms of a Carbazole and Pyrazole Containing Anticancer Compound
Current Cancer Drug Targets Separation of Ginseng Active Ingredients and their Roles in Cancer Metastasis Supplementary Therapy
Current Drug Metabolism Design, Synthesis and Evaluation of Peroxisome Proliferator-Activated Receptor α/βDual Agonists for the Treatment of Type 2 Diabetes
Letters in Drug Design & Discovery Recent Advances and Strategies in Tumor Vasculature Targeted Nano-Drug Delivery Systems
Current Pharmaceutical Design Current Advances in the Development of Anticancer Drugs Targeting Tyrosine Kinases of the Src Family
Current Drug Therapy Chitosan: A Propitious Biopolymer for Drug Delivery
Current Drug Delivery Analysis of Taiwan Patents for the Medicinal Mushroom “Niu-Chang- Chih”
Recent Patents on Food, Nutrition & Agriculture Bioactive Milk Lipids
Current Nutrition & Food Science Cannabis-Derived Substances in Cancer Therapy – An Emerging Anti- Inflammatory Role for the Cannabinoids
Current Clinical Pharmacology Roles of SM22α in Cellular Plasticity and Vascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets